Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.77 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.77 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.77 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11825400 | 0.93 | EHMT2 (0.81) | EHMT2EHMT1APOBEC3GHPGDMAPT | |
| SCHEMBL21174 | 0.88 | EHMT2 (1.00) | EHMT2EHMT1APOBEC3GHPGDMAPT | |
| SCHEMBL29349787 | 0.88 | EHMT2 (1.00) | EHMT2EHMT1APOBEC3GHPGDMAPT | |
| SCHEMBL27972393 | 0.88 | EHMT2 (1.00) | EHMT2EHMT1APOBEC3GHPGDMAPT | |
| SCHEMBL11824315 | 0.87 | EHMT2 (0.71) | EHMT2EHMT1APOBEC3GHPGDMAPT | |
| Hydrochloric Acid SCHEMBL8671988 | 0.85 | EHMT2 (0.94) | EHMT2EHMT1APOBEC3GHPGDMAPT | |
| Hydrochloric Acid SCHEMBL11726971 | 0.85 | EHMT2 (0.94) | EHMT2EHMT1APOBEC3GHPGDMAPT | |
| Hydrochloric Acid SCHEMBL10707236 | 0.85 | EHMT2 (0.94) | EHMT2EHMT1APOBEC3GHPGDMAPT | |
| Ammonia Solution, Strong SCHEMBL421495 | 0.85 | EHMT2 (0.94) | EHMT2EHMT1APOBEC3GHPGDMAPT | |
| Hydrogen Sulfide SCHEMBL3347200 | 0.85 | EHMT2 (0.94) | EHMT2EHMT1APOBEC3GHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361260-A1 | NUCLEOTIDE ANALOGUES | SINGULAR GENOMICS SYSTEMS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12215122-B2 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240400602-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-12-05 | — | — | US | disclosed |
| US-12145960-B2 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240336711-A1 | REAGENTS AND METHODS FOR ALIPHATIC CARBON-HYDROGEN BOND FUNCTIONALIZATION | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2024-10-10 | — | — | US | disclosed |
| US-20240316036-A1 | DISULFIDE CONTAINING THERAPEUTICS AND DIAGNOSTICS | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-09-26 | — | — | US | disclosed |
| US-20240269156-A1 | DISULFIDE CONTAINING THERAPEUTICS | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-08-15 | — | — | US | disclosed |
| US-20240174709-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-05-30 | — | — | US | disclosed |
| US-11958877-B2 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2024-04-16 | — | — | US | disclosed |
| US-11878993-B2 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2024-01-23 | — | — | US | disclosed |
| WO-2022241129-A1 | REAGENTS AND METHODS FOR ALIPHATIC CARBON—HYDROGEN BOND FUNCTIONALIZATION | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022093800-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| CN-113039191-A | Nucleotide analogs | 奇异基因组学系统公司 | 2021-06-25 | — | — | CN | disclosed |
| CN-110314238-A | A kind of polypeptide drugs conjugate of cancer target and its preparation method and application | 烟台药物研究所 | 2019-10-11 | — | — | CN | disclosed |
| CN-110314235-A | A kind of reduction response type amphipathic stem antitumor medicine conjugate and its preparation method and application | 烟台药物研究所 | 2019-10-11 | — | — | CN | disclosed |
| US-20180008543-A1 | Cleavable Lipids | RANA THERAPEUTICS, INC. | 2018-01-11 | — | — | US | disclosed |
| US-9764036-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-09-19 | — | — | US | disclosed |
| US-9764036-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-09-19 | — | — | US | disclosed |
| US-20160213785-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-07-28 | — | — | US | disclosed |
| US-20160213785-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213785-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | EHMT2 3480/4885EHMT1 3858/4885APOBEC3G 1504/4885 |
| US-20240336711-A1 | REAGENTS AND METHODS FOR ALIPHATIC CARBON-HYDROGEN BOND FUNCTIONALIZATION | NCF1, SHROOM3, NPM1 | EHMT2 286/4885EHMT1 367/4885APOBEC3G 1744/4885 |
| US-12215122-B2 | Nucleotide analogues | NUDT1, POLN, TYMP | EHMT2 2494/4885EHMT1 2450/4885APOBEC3G 226/4885 |
| US-20240400602-A1 | NUCLEOTIDE ANALOGUES | ADAR, NUDT1, NSUN2 | EHMT2 938/4885EHMT1 923/4885APOBEC3G 236/4885 |
| US-20240316036-A1 | DISULFIDE CONTAINING THERAPEUTICS AND DIAGNOSTICS | GPX1, GPX4, PDIA4 | EHMT2 2946/4885EHMT1 3031/4885APOBEC3G 4047/4885 |
| US-20250361260-A1 | NUCLEOTIDE ANALOGUES | ADAR, NUDT1, NSUN2 | EHMT2 938/4885EHMT1 923/4885APOBEC3G 236/4885 |
| US-20180008543-A1 | Cleavable Lipids | PTDSS2, ACSS2, SARS1 | EHMT2 3647/4885EHMT1 3920/4885APOBEC3G 2669/4885 |
| US-20240269156-A1 | DISULFIDE CONTAINING THERAPEUTICS | P4HB, PDIA5, PDIA4 | EHMT2 3151/4885EHMT1 3191/4885APOBEC3G 2768/4885 |
| US-11958877-B2 | Nucleotide analogues | ITPA, POLB, NUDT1 | EHMT2 2878/4885EHMT1 3389/4885APOBEC3G 437/4885 |
| US-20240174709-A1 | NUCLEOTIDE ANALOGUES | NUDT1, POLN, TYMP | EHMT2 2494/4885EHMT1 2450/4885APOBEC3G 226/4885 |
| US-11878993-B2 | Nucleotide analogues | ITPA, POLB, NUDT1 | EHMT2 2878/4885EHMT1 3389/4885APOBEC3G 437/4885 |
| US-12145960-B2 | Nucleotide analogues | ITPA, POLB, NUDT1 | EHMT2 2878/4885EHMT1 3389/4885APOBEC3G 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.